Aiman Waheed

Dr. Aiman Waheed

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 May 2024 in World Neurosurgery
Verified
Journal Article
Closed access
AAAsma Ahmed
Asma Ahmed
AWAiman Waheed
Aiman Waheed
EYEesha Yaqoob
Eesha Yaqoob
RJRukhsana Jabeen
Rukhsana Jabeen
Bipin ChaurasiaBipin Chaurasia
Bipin Chaurasia
SJSaad Javed
Saad Javed

22 June 2024 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
AWAiman Waheed
Aiman Waheed
Bipin ChaurasiaBipin Chaurasia
Bipin Chaurasia

7 February 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AWAiman Waheed
Aiman Waheed
MGMuhammad Hamza Mbbs Gul
Muhammad Hamza Mbbs Gul
BIBadr Ilmaguook
Badr Ilmaguook
AWAbdul Baseer Mbbs Wardak
Abdul Baseer Mbbs Wardak
FSFnu Sadeed
Fnu Sadeed
SASarah Mbbs Ahmad
Sarah Mbbs Ahmad
Warts, Hypogammaglobulinemia, recurrent bacterial Infections, and Myelokathexis syndrome is a rare autosomal dominant disorder characterized by gain-of-function mutations in chemokine receptor type-4 (CXCR4 receptor). The acronym WHIM stands for Warts, Hypogammaglobulinemia, recurrent bacterial Infections, and Myelokathexis. Traditionally, WHIM syndrome has been managed with intravenous immunoglobulin (IVIG) and filgrastim (granulocyte colony-stimulating factor). Intravenous immunoglobulin is used to provide passive immunity to counteract hypogammaglobulinemia, while filgrastim stimulates the production and release of neutrophils from the bone marrow to address neutropenia. However, these treatments have limited efficacy, require frequent administration, and involve significant costs and patient burden. The recent Food and Drug Administration (FDA) approval of Mavorixafor, a small-molecule CXCR4 antagonist, marks a significant advancement in the management of WHIM syndrome. Mavorixafor enhances white blood cell mobilization from the bone marrow, directly targeting the underlying cause of the disease. In a pivotal phase-3 trial conducted by Badalato et al, involving 30 participants randomized to receive Mavorixafor 400 mg daily or placebo for 52 weeks, Mavorixafor demonstrated a statistically significant increase in absolute neutrophil count (P < 0.01) and a notable reduction in annual infection frequency compared to placebo. Additionally, a Phase-2 study reported a 75% reduction in cutaneous warts and an annual infection rate of 2.27 occurrences with adequate dosing. Mavorixafor maintained a favorable safety profile and required fewer administration complexities than IVIG and filgrastim, with 78% of patients achieving an overall response compared to 10% in the placebo group. These findings underscore the potential of Mavorixafor to significantly improve clinical outcomes for patients with WHIM syndrome, offering a more effective and targeted treatment option. The approval of Mavorixafor not only enhances current therapeutic strategies but also paves the way for future research into CXCR4 antagonists, potentially revolutionizing the management of WHIM syndrome and similar immunodeficiencies.

20 September 2024 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
AWAiman Waheed
Aiman Waheed
MGMuhammad Hmaza Gul
Muhammad Hmaza Gul
AWAbdul Baseer Mbbs Wardak
Abdul Baseer Mbbs Wardak
Hafsa Arshad Azam RajaHafsa Arshad Azam Raja
Hafsa Arshad Azam Raja
HHHelai Hussaini
Helai Hussaini
An abstract is unavailable. This article is available as a PDF only.

12 July 2024 in Neurosurgical Review
Verified
Journal Article
Closed access
PDF file
AWAiman Waheed
Aiman Waheed
MGMuhammad Hmaza Gul
Muhammad Hmaza Gul
Bipin ChaurasiaBipin Chaurasia
Bipin Chaurasia

5 March 2025 in Annals of Medicine & Surgery
Verified
Journal Article
Open access
MGMuhammad Hmaza Gul
Muhammad Hmaza Gul
AWAiman Waheed
Aiman Waheed
MJMayank Sujeetkumar Jha
Mayank Sujeetkumar Jha
AWAbdul Baseer Mbbs Wardak
Abdul Baseer Mbbs Wardak
BIBadr Ilma
Badr Ilma
UKUmer Mbbs Khan
Umer Mbbs Khan